Medicare Part D must cover one weight-management GLP-1 starting April 1, 2026

Medicare Part D plans are required to cover at least one GLP-1 medication approved for chronic weight management as of April 1, 2026, under the Treat and Reduce Obesity Act signed into law in late 2025 ^[1]. Covered prescriptions are capped at a $50 monthly copay and are exempt from the Part D deductible ^[1].

The change reverses a Medicare exclusion for weight-loss drugs that dates to 2003. Formulary inclusion is mandatory for Part D plans, but plans keep flexibility over which specific products they list, how they tier them, and what prior authorization they require ^[1].

Which medications and what they cost

The GLP-1s with FDA approval for weight loss as of April 2026 are Wegovy (semaglutide) in injectable and oral form, and Zepbound (tirzepatide) ^[1]. The guide reviewed here lists no others.

Ozempic and Rybelsus (both semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes, not obesity, so Medicare covers them for diabetes but not for weight loss ^[1]. Compounded semaglutide and compounded tirzepatide are not covered; only FDA-approved brand-name products are eligible ^[1]. Rybelsus is also listed as not covered for weight management ^[1].

List prices cited by the same guide are about $1,349 a month for injectable Wegovy, about $499 for oral Wegovy, and about $1,060 for Zepbound, against a patient cost of $50 or less for a covered prescription ^[1]. The $50 figure is described as a ceiling that plans may undercut but cannot exceed ^[1]. The standard Part D annual out-of-pocket maximum of $2,000 also applies ^[1].

CMS estimated the benefit would add $2 to $7 a month to Part D premiums, though the guide notes premium changes vary by plan ^[1].

Who qualifies

Coverage requires active Part D enrollment, either a standalone drug plan or a Medicare Advantage plan with drug coverage ^[1]. The clinical criteria are a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease ^[1]. A prescriber must document the indication, and most plans are requiring prior authorization ^[1]. Some plans may also use step therapy, requiring one medication to be tried before another is covered ^[1]. Standard prior authorization decisions are described as taking about one to two weeks, with expedited review for urgent cases ^[1].

Roughly 14 million Medicare beneficiaries with obesity may become eligible, according to the guide ^[1].

CMS announced on May 6, 2026 that the Medicare GLP-1 Bridge, a time-limited demonstration, will provide eligible Part D enrollees access to certain GLP-1 medications for $50 per monthly supply from July 1, 2026 through December 31, 2027 ^[2]. "These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," CMS Administrator Dr. Mehmet Oz said in the announcement ^[2]. Chris Klomp, Director of Medicare and Chief Counselor at HHS, said the demonstration is designed to make access "simpler, more predictable, and more consistent across the Medicare program" ^[2].

The two timelines are described differently across the two sources. The coverage guide states the $50 copay cap is scheduled to begin July 1, 2026 under the Bridge program, while also describing the $50 cap as part of the April 1 requirement ^[1]. CMS places the $50 program start at July 1, 2026 ^[2].

Why it matters for patients

For Medicare enrollees who qualify, the practical effect is a fixed, predictable monthly cost for a covered GLP-1 instead of a list price near or above $1,000 ^[1]. Because anti-obesity medications are exempt from the deductible, that $50 does not sit behind a deductible phase ^[1].

Access still depends on the individual plan. A plan must cover at least one weight-management GLP-1, but not necessarily the one a patient wants, and prior authorization or step therapy can add delays ^[1]. People taking compounded semaglutide or tirzepatide would need a brand-name prescription to use the benefit, since compounded products cannot be billed to Medicare ^[1]. Whether a given telehealth prescriber accepts Medicare also varies by company ^[1]. Manufacturer savings cards are described as unnecessary for people using the Medicare benefit, because the cap already applies ^[1].

What happens next

The Medicare GLP-1 Bridge begins July 1, 2026 and runs through December 31, 2027 ^[2]. CMS said it will share more information for beneficiaries as the program begins and is working with providers, pharmacies and manufacturers on implementation ^[2]. Separately, CMS has announced the BALANCE integrated care model, scheduled for July 2026, which would add dietitian, behavioral health and exercise support alongside prescribing; it is optional and not required for medication coverage ^[1]. CMS is expected to publish a list of participating BALANCE providers when that program launches ^[1].